Skip to main content
Home
  • 服务
    服务

    我们的服务涵盖产品开发和商业化的整个生命周期,既适用于小型本地试验,也适用于大型全球项目。

    Read More
    临床研究服务 商业定位 咨询服务 早期服务 战略性解决方案 语言服务 实验室服务 医学影像服务 真实世界洞察 研究中心及患者解决方案
    clinical-trials-china.jpeg
    COVID-19的临床试验

    Clinical trials during COVID-19.

    clinical-trials-china-2.jpeg
    研究中心和患者

    研究中心和患者识别,入组和参与

  • 治疗领域
    治疗领域

    我们在广泛的治疗领域拥有丰富的经验。我们管理所有主要地区的研究,与世界领先的研究人员建立了稳固的工作关系。

    Read More
    心血管系统 细胞和基因疗法(CGT) 中枢神经系统 内分泌与代谢疾病 感染性疾病 内科与免疫学 医疗器械 肿瘤学 儿科学 罕见病与孤儿病 移植免疫学 女性健康
    icon-china-mega-menu-image.jpeg
    疫苗

    ICON 领导了 18 种疫苗的开发,获得了 FDA/EMA 的批准,其中包括世界上第一个获批的 COVID-19 疫苗

    icon-china-mega-menu-image-2.jpeg
    治疗领域洞察

    ICON 的治疗专家定期为行业出版物内容做出贡献。

  • 加入我们
  • 新闻和活动
  • ICON中国
    ICON中国
    Read More
    ICON中国 公司历史 我们的荣誉 Leadership 联系我们
    china-checkmark.jpeg
    环境、社会与治理(ESG)

    ICON 致力于对我们的员工、环境和社区产生积极影响。

    china-discussion.jpeg
    ICON和你

    合作有所作为

  • 中国大陆办公室
  • 商务合作
  1. Home
  2. 新闻和活动
  3. 活动一览
  4. Webinars
  5. The Rare Disease Revolution

The Rare Disease Revolution

Real world evidence is expected to play a major role in the approval of future new medicines

  • Date 25 January 2018
    Time 16:00 - 17:00
    Location Webinar
    Timezone Europe/London

    New regulatory developments in both the US and Europe are promoting a radical change to accelerate the approval of new medications for rare disease. These include the 21st Century Cure Act in the US and the Adaptive Regulatory Pathway in Europe.

On-Demand Webinar Archive

To access the archived recording of this webinar, visit our webinar channel and complete a one time only form. This will give you access to our entire library of archived webinars.

Access Webinar Archive

Overview

While very exciting for rare disease drug development, the differences from traditional drug development require attention to multiple areas, including small patient populations, more occurrence in paediatric patients, and complicated presentation of disease.

These small populations make it both practically and ethically difficult to conduct multiple confirmatory efficacy trials. There may be no established treatment standards so the design of the registration studies may involve use of a RWE approach to observe changes in clinical status over time rather than comparisons of drug effect relative to a placebo or comparator therapy.

The study process also needs to recognize changes in the patient’s disease and lifestyle and adapt both the study design and methods to a more patient-focused approach. Many rare diseases have strong patient advocacy groups that can aid in the design and execution of rare disease registries to identify and engage rare disease patients as part of clinical development

Key speakers

Jim Carroll

Vice President, Real World Evidence Strategy & Analytics Commercialisation and Outcomes, ICON

Jim Carroll oversees the development of real world data (RWD) and technology based solutions to support sponsors who are seeking to expand labelling and market access, while staying ahead of the growing demand for evidentiary requirements. Jim has over 20 years’ CRO and pharmaceutical experience and joins ICON from inVentiv Health, where he led the formation of a new business unit focused on providing novel RWD-driven services. Jim previously worked at IMS Health (now IQVIA), where he led the development and commercialization of innovative RWD-based, global analytic solutions to improve decision outcomes across the biopharmaceutical product lifecycle.

William C. Maier, PhD

Chief Scientific Officer, Mapi, an ICON plc company

Dr. Maier has over 20 years of experience in drug development and commercialization at pharmaceutical companies in Europe, Canada, the United States and Asia. He works with pharmaceutical companies throughout the world to provide regulatory, strategic and scientific guidance on medical treatment development and commercialisation. He is an expert in Real World Evidence and has worked with companies on the design, conduct and approval of over 100 observational studies related to biotechnology, consumer products, pharmaceuticals, drug development and product commercialisation.

In this section
In this section
  • In the News
  • Press releases
  • 活动一览
    • Industry events
    • Webinars
    • Workshops
  • DIA China 2022

Connect with us

  • Contact us
  • Submit proposal request
  • Update Email Preferences
  • Global office locator
  • ICON on social media
Site Branding
    ICON plc
  • Contact
  • Results & Reports
For Clients
  • 我们的服务
  • 治疗领域
ICON for
  • 新 闻
  • 加入我们
News & Events
  • 中国大陆办公室
  • 商务合作
Socials
  • WeChat QR code

Legal Footer

  • © 2025 ICON plc
  • Disclaimer
  • Privacy
  • Cookies
How can we help?
  • All
Popular search terms:
  • COVID-19
  • Site & Patient Recruitment
  • Oncology
  • Medical Device
  • Real World Evidence
  • Decentralised & hybrid clinical trials
  • Digital Disruption